"Though the purchase price is essentially in line with CPHD's 52-week high ($53.19), we think its implied multiple of ~6x EV/NTM Sales is fair. We note that Cepheid's average EV/NTM Sales multiple is ~5.7x on a 10-year basis and ~6.1x on a five-year basis," analyst Karen Koski wrote in a note.
Koski also said there will be no anti-trust/Federal Trade Commission (FTC) issues over the deal given relatively limited product overlap.
Meanwhile, the analyst noted that Cepheid's senior leaders, engineers and sales people would need to be on board for Danaher to reap the benefits.
"Given DHR's organizational structure, we expect Cepheid to enjoy the necessary flexibility to operate independently, yet still benefit from R&D and commercial collaborations with DHR's other diagnostics businesses," Koski added.
Koski has downgraded Cepheid to Neutral following the takeover deal.
Shares of Cepheid closed Tuesday's regular trading at $52.53 and were flat on the day Wednesday at time of writing.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.